Bicara Therapeutics Inc.
About Bicara Therapeutics Inc.
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$137.9M
- Total assets
- $431.0M
- Market cap
- $1.3B
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $155.6M
- Operating income
- -$155.6M
- Income tax
- $217.0K
- Net income
- -$137.9M
- EPS (basic)
- $-2.52
- EPS (diluted)
- $-2.52
Balance sheet
- Total assets
- $431.0M
- Current assets
- $422.1M
- Total liabilities
- $29.5M
- Current liabilities
- $28.9M
- Shareholders’ equity
- $401.5M
Cash flow
- Operating cash flow
- -$106.8M
- Investing cash flow
- -$318.5M
- Financing cash flow
- $32.3M
- Net cash flow
- -$393.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.3B
- EPS (diluted)
- $-2.52
- Shares outstanding
- 65.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 13, 2024
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $137.9M.
- Trading 16% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Bicara Therapeutics Inc..
Write a review
News about Bicara Therapeutics Inc.
News & sentiment via Polygon.io
